ReviewFrontiers in endocrinology2026
Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD), and subsequently to metabolic dysfunction-associated steatotic liver disease (MASLD), signals a paradigm shift that repositions hepatic steatosis as a systemic metabolic disorder rather than a diagnosis by exclusion. This review synthesizes the evidence supporting the nomenclature transition, examines the pathogenic mechanisms driving disease progression, evaluates the clinical implications of the lean MAFLD phenotype, and surveys the evolving therapeutic landscape. Oxidative stress, chronic low-grade inflammation, and mitochondrial dysfunction form an interconnected network propelling the trajectory from simple steatosis to steatohepatitis and fibrosis. The bidirectional liver-adipose tissue communication axis, modulated by micronutrient homeostasis, has emerged as an integrative framework for understanding disease pathobiology. Lean MAFLD, present in 20-40% of affected individuals despite normal body mass index, challenges obesity-centered screening approaches and underscores the necessity of metabolic phenotyping in routine clinical practice. Extrahepatic complications-particularly subclinical cardiovascular injury, type 2 diabetes-associated hepatocellular carcinoma, and cardiomyopathy-remain the principal causes of death in this population. The regulatory approval of resmetirom in March 2024, together with promising phase II data on incretin-based therapies, FGF21 analogs, and PPAR modulators, has begun to reshape a therapeutic field that had long relied on lifestyle modification alone. We also discuss the gut-liver axis, genetic predisposition, economic burden, and multidisciplinary management models that together define the contemporary understanding of this disease. This review integrates these developments and identifies key gaps warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.